Laurus Labs
Laurus Labs Limited, commonly referred to as Laurus Labs, is a prominent player in the pharmaceutical industry, headquartered in Hyderabad, India. Founded in 2005, the company has established itself as a leader in the development and manufacturing of active pharmaceutical ingredients (APIs), generic formulations, and contract research services. With a strong focus on high-quality production, Laurus Labs offers a diverse portfolio that includes antiretroviral, oncology, and cardiovascular products, setting itself apart through its commitment to innovation and regulatory compliance. The company has achieved significant milestones, including multiple approvals from global regulatory authorities, which solidify its market position. Recognised for its robust research and development capabilities, Laurus Labs continues to expand its operational footprint across various regions, contributing to its reputation as a trusted partner in the pharmaceutical sector.
DitchCarbon Score
How does Laurus Labs's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Laurus Labs's score of 37 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Laurus Labs's reported carbon emissions
In 2023, Laurus Labs reported total carbon emissions of approximately 375,460,000 kg CO2e, comprising 198,782,000 kg CO2e from Scope 1, 159,094,000 kg CO2e from Scope 2, and 87,212,000 kg CO2e from Scope 3 emissions. This reflects a commitment to transparency in their emissions reporting, with data disclosed across all three scopes. In 2022, the company recorded total emissions of about 360,398,000 kg CO2e, with Scope 1 emissions at 135,804,000 kg CO2e, Scope 2 at 159,094,000 kg CO2e, and Scope 3 at 65,014,000 kg CO2e. The emissions intensity per unit of revenue has shown a slight increase, indicating a need for ongoing efforts in emissions reduction. Laurus Labs has committed to near-term emissions reduction targets but has not set a net-zero target as of now. The company operates within the Pharmaceuticals, Biotechnology, and Life Sciences sector and is actively working towards improving its sustainability practices. Their emissions intensity metrics suggest a focus on reducing carbon output relative to revenue, which is crucial for aligning with industry standards and expectations. Overall, Laurus Labs is taking steps to address its carbon footprint while navigating the challenges of the pharmaceutical industry, with a clear commitment to enhancing its climate strategies in the coming years.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 68,321,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 248,303,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Laurus Labs is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
